Included In Bausch’s Planned Spin-Off, Consumer Brands Account For 3 Spots In Its Top 10 List
Executive Summary
Sales of its segment leaders Ocuvite and PreserVision vision health supplements, Lumify OTC eye drops and other consumer lines were down a reported 13% to $321m in the second quarter.
You may also be interested in...
Bausch Considers Proposal For COVID-19 Drug: Lumify Eye Drops Inactivate Virus In Lab Tests
Bausch Health says its Lumify OTC redness reliever drops showed "complete inactivation" of COVID-19 in time-kill tests, with preservative compound benzalkonium chloride apparently the key reason. The in vitro findings prompted it to consider discussions with regulatory agencies on proposing a remedy for the virus.
PreserVision, Biotrue Brands Help Bausch US Consumer Health See Turnaround More Clearly
Bausch + Lomb’s PreserVision supplement sales grew 17% in Q3, driving 11% growth its US consumer health business. CEO Joseph Papa says Bausch is “making great progress and expect the internal organization design” of its planned spin-off of Bausch + Lomb to be completed in a year.
Consumer Health Brands On Nielsen ‘Breakthrough’ Leaders List Include Lumify As ‘Superstar’
“We selected Lumify based on its strong business performance in years one and two, and the success it had in growing a category through premiumization," says Nielsen’s BASES leader, Ben Macedo.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: